Alnylam Pharmaceuticals, Inc.
NASDAQ:ALNY
Overview | Financials
Company Name | Alnylam Pharmaceuticals, Inc. |
Symbol | ALNY |
Currency | USD |
Price | 268.95 |
Market Cap | 34,689,439,950 |
Dividend Yield | 0% |
52-week-range | 141.98 - 304.39 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Yvonne L. Greenstreet M.B.A., MBA, MBChB |
Website | https://www.alnylam.com |
An error occurred while fetching data.
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD